Business Insider

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity ...
Nasdaq

Assembly Biosciences Reports Promising Interim Results for ABI-4334 in Phase 1b Study for Chronic Hepatitis B Virus Infection

ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
Nasdaq

Assembly Biosciences Reports Positive Phase 1b Results for ABI-4334 in Chronic HBV Infection, Supporting Collaboration with Gilead Sciences

Assembly Biosciences reported positive Phase 1b results for ABI-4334 in chronic HBV, showing strong antiviral activity and favorable safety. Assembly Biosciences, Inc. has announced positive results ...
Pharmabiz

Assembly Bio announces interim phase 1b results from trial evaluating next-generation CAM candidate ABI-4334 in chronic hepatitis B

Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases, announced encouraging interim safety, pharmacokinetic (PK) and efficacy results ...